IGF-1 LR3 (Insulin-like Growth Factor-1 Long Arg3) is a synthetic analog of human insulin-like growth factor-1 that has been engineered for enhanced potency and extended biological activity in experimental systems. This 83-amino acid peptide differs from native IGF-1 through substitution of glutamic acid at position 3 with arginine and the addition of a 13-amino acid N-terminal extension peptide. These structural modifications dramatically reduce binding affinity for IGF-binding proteins (IGFBPs), which normally sequester and regulate native IGF-1 in biological fluids.
As a consequence, IGF-1 LR3 exhibits substantially greater bioavailability and prolonged receptor interaction in cell culture systems compared to the wild-type peptide. In laboratory research, IGF-1 LR3 is utilized to study the IGF-1 receptor (IGF-1R) signaling axis, including its downstream activation of the PI3K-Akt-mTOR and Ras-MAPK pathways — two of the most extensively studied signal transduction cascades in modern cell biology. Researchers investigating cellular proliferation, differentiation, survival signaling, and metabolic regulation employ IGF-1 LR3 as a potent and convenient tool for activating IGF-1R-dependent processes with minimal confounding from IGFBP sequestration.
The peptide is supplied as a lyophilized powder with full purity documentation. flowptides Peptides provides IGF-1 LR3 for use exclusively in legitimate laboratory research settings. It is not intended for human or animal use.
FDA DISCLAIMER
The information provided on this website has not been evaluated by the U.S. Food and Drug Administration (FDA). None of the statements herein, nor any of the products offered, are intended to diagnose, treat, cure, or prevent any medical condition.
All products are supplied strictly as laboratory research reagents and are not for human consumption. We do not provide products to patients and do not make any claims regarding medical use.
flowptides Peptides operates solely as a chemical supplier. It is not a compounding pharmacy and does not operate as a compounding facility under Section 503A of the Federal Food, Drug, and Cosmetic Act.
jose Franco –
Flowptides is the move.
just got my igf order in and it’s fire. packaging was super discrete and secure. really happy with the purity so far—no cloudiness at all when i mixed it. if you need high quality research stuff and don’t want to wait 3 weeks, hit these guys up.